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Certain forms of the heavy metals arsenic and chromium are considered human carcinogens,
although they are believed to act through very different mechanisms. Chromium(VI) is believed to
act as a classic genotoxic and mutagenic agent, and DNANchromatin appears to be the principal
target for its effects. In contrast, arsenic(lll) is considered nongenotoxic, but is able to target
specific cellular proteins, principally through sulfhydryl interactions. We had previously shown that
various genotoxic chemical carcinogens, including chromium(VI), preferentially altered expression
of several inducible genes but had little or no effect on constitutive gene expression. We were
therefore interested in whether these carcinogenic heavy metals might target specific but distinct
sites within cells, leading to alterations in gene expression that might contribute to the
carcinogenic process. Arsenic(lll) and chromium(V1) each significantly altered both basal and
hormone-inducible expression of a model inducible gene, phosphoenolpyruvate carboxykinase
(PEPCK), at nonovertly toxic doses in the chick embryo in vivo and rat hepatoma H411E cells in
culture. We have recently developed two parallel cell culture approaches for examining the
molecular basis for these effects. First, we are examining the effects of heavy metals on
expression and activation of specific transcription factors known to be involved in regulation of
susceptible inducible genes, and have recently observed significant but different effects of
arsenic(lll) and chromium(Vl) on nuclear transcription factor binding. Second, we have developed
cell lines with stably integrated PEPCK promoter-luciferase reporter gene constructs to examine
effects of heavy metals on promoter function, and have also recently seen profound effects
induced by both chromium(V1) and arsenic(lil) in this system. These model systems should
enable us to be able to identify the critical cis (DNA) and trans (protein) cellular targets of heavy
metal exposure leading to alterations in expression of specific susceptible genes. It is anticipated
that such information will provide valuable insight into the mechanistic basis for these effects as
well as provide sensitive molecular biomarkers for evaluating human exposure. Environ Health
Perspect 1 06(Suppl 4):1 005-1015 (1998). http://ehpnet1.niehs.nih.gov/docs/1998/Suppl4/
1005-1015hamilton/abstract.html
Key words: chromium, arsenic, mitomycin C, phosphoenolpyruvate carboxykinase,
transcription factors, genetic constructs, transfection
This paper is based on a presentation at the Symposium on the Superfund Basic Research Program: A Decade
of Improving Health through Multi-Disciplinary Research held 23-26 February 1997 in Chapel Hill, North
Carolina. Manuscript received at EHP 1 1 December1997; accepted 27 March 1998.
The authors dedicate this manuscript to the memory of the late Dr. Karen E. Wetterhahn, who was an invalu-
able scientist, mentor, colleague, and friend. Dr. Wetterhahn and her laboratory provided reagents, laboratory
resources, and valuable advice on this project. Most important, Dr. Wetterhahn was the original director and the
major impetus behind the Dartmouth Superfund Basic Research Program Project which made this research pos-
sible. The authors also wish to thank A. Barchowsky and his lab for their advice and assistance in the gel shift
analysis. This work was supported by grants to JWH from NIH-NIEHS (ES07373), NIH-NCI (CA49002), and the
Norris Cotton Cancer Center. JWH was also partially supported by the N6rris Cotton Cancer Center; RCK and
OVB were supported by fellowships from NIH-NIEHS (ES07373) and AJW was partially supported by the
Dartmouth College Chemistry Department. Support for the Dartmouth College Molecular Biology Core Facility
was provided by NIH-NIEHS (ES07373) and the Norris Cotton Cancer Center Core grant (CA23108).
Address correspondence to J.W. Hamilton, Department of Pharmacology and Toxicology, 7650 Remsen,
Dartmouth Medical School, Hanover NH 03755-3835. Telephone: (603) 650-1316. Fax: (603) 650-1129. E-mail:josh.hamilton@dartmouth.edu
Abbreviations used: EMSA, gel electrophoretic mobility shift assay; MMC, mitomycin C; MMS, methyl
methanesulfonate; PEPCK, phosphoenolpyruvate carboxykinase; TNFa, tumor necrosis factor a; TNFOi, tumor
necrosis factor P; U.S. EPA, U.S. Environmental Protection Agency; UV, ultraviolet.
Introduction
The heavy metals chromium(VI) and
arsenic(III) are considered human carcino-
gens and share several properties in regard
to their carcinogenicity. They are both asso-
ciated with certain tumors in humans based
principally on epidemiologic evidence that
is quite strong and that preceded animal
carcinogenicity data by many years (1-3).
Both are considered lung carcinogens
whose effects are synergistic with cigarette
smoking or exposure to other lung carcino-
gens such as benzo[a]pyrene or other car-
cinogenic metals. Human exposure to these
metals occurs principally in occupational
settings and through environmental conta-
minations such as from toxic waste sites,
including numerous Superfund sites, or
from naturally contaminated drinking
water. Chromium and arsenic are listed as 2
of the 8 heavy metals that are among the
top 22 compounds of particular concern to
the U.S. Environmental Protection Agency
(U.S. EPA) Office of Solid Waste and
Emergency Response concerning Superfund
sites. Thus, there is now increasing concern
about human health effects from exposure
to heavy metals found in high concentra-
tions at these sites, such as the high levels of
chromium and arsenic at waste sites in
Woburn, Massachusetts, and northern New
Jersey. However, potential human expo-
sures and health risk from these sites are less
well defined. Thus, understanding the
overall human health impact of environ-
mental exposure to these heavy metals is of
paramount concern.
Chromium(VI) is a known human lung
carcinogen and may also contribute to
nasopharyngeal cancers (1,2,4,5). A strong
association between chromium exposure
and an increase in lung cancer was first
observed in the chrome ore industry in
Germany in the 1920s. Since then, there
have been numerous studies linking inhala-
tion exposure to chromium, particularly
chromium(VI) compounds, with increases
in lung and nasal cancers. However, early
recognition of this association and signifi-
cant decreases in exposure through indus-
trial hygiene practices have reduced these
incidences. Arsenic is considered to be a
probable human lung, skin, and bladder
carcinogen (3,6). Lung exposure has been
principally through occupational settings in
the mining, processing, and smelting of
arsenic-containing ores, and in the manu-
facture of arsenic-containing pesticides,
whereas skin exposure has been through
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many of these same occupational settings as
well as topical application of arsenical
medications. There is also an association
between environmental arsenic exposure,
e.g., through arsenic in well water, and an
increased risk of certain skin and possibly
bladder cancers (3,7). Arsenic exposure has
also been implicated in certain other tumor
incidences including scrotal cancer (copper
smelters) and hepatic angiosarcomas (vine-
yard workers) (3,7). As with the other
carcinogenic metals, there is a strong syner-
gistic association between arsenic exposure
and cigarette smoking for risk of lung
cancer. However, in the case of arsenic, this
is complicated by the fact that there were
high levels of arsenic in tobacco prior to the
1970s as a result of use of arsenical pesti-
cides in tobacco agriculture (3). Arsenic has
only recently been shown to be carcinogenic
in animal models (3).
The form and valence of chromium is a
major factor in assessing its biologic effects,
and chromium(VI) is the principal form
responsible for the mutagenic and carcino-
genic properties, as first proposed in the
uptake-reduction model by Wetterhahn and
co-workers (1,4,8,9). Chromium(VI) has
been shown to be genotoxic, mutagenic, and
carcinogenic in a large number of short- and
long-term assay systems using various end
points and systems (1,2,4,8,9). Like many
organic carcinogens such as benzo[a]pyrene
and aflatoxin B1, chromium(VI) appears to
act as a classic initiator in these test systems,
and this is believed to be the principal
mechanism by which chromium(VI)
increases carcinogenic risk. Our laboratory
has hypothesized that genotoxic carcinogens,
including chromium(VI), exert preferential
effects on the expression of a specific dass of
genes, i.e., inducible genes, as a result of
nonrandom DNA damage targeted to mem-
bers of this gene class (8-12). Previous
studies in our laboratory have shown that a
number of different genotoxic chemical car-
cinogens that induce different types ofDNA
damage, including the genotoxic metals
chromium and nickel, significantly alter
both basal and inducible expression of
several model inducible genes but have no
effect on expression of constitutive genes.
Assuming that the effects on gene expression
are a result of carcinogen-induced DNA
damage, what is their molecular basis?
We have postulated that inducible
genes are strongly affected by chemically-
induced DNA damage as a result of both
targeting ofDNA damage and the intrinsic
structural and biochemical properties of
those genes, and have proposed a model in
which these effects occur as a consequence
of chromatin structure and/or nuclear
architecture (10,13). This nuclear model
provides a framework for understanding
how two different genes in the same
nucleus may reside in very different physi-
cal and chemical environments, and may
therefore have different sensitivities to
chemical attack. Thus, even low levels of
DNA damage in vivo might be sufficient to
have significant effects on expression of
certain sensitive genes. We previously
demonstrated that treatment of 14-day
chick embryos with a single administration
of chromium(VI), at a dose that produced
no overt toxicity but that caused significant
levels ofDNA damage (14), had profound
effects on expression of several inducible
genes while having no effect on expression
of several constitutively expressed genes
(10). Both the basal and inducible expres-
sion of the inducible 5'-aminolevulinate
synthase, cytochrome P450 CYP2HI, and
phosphoenolpyruvate carboxykinase
(PEPCK) genes were markedly affected by
the chromium treatment, whereas the albu-
min, transferrin, and ,-actin genes were
refractory to this treatment. The effects on
expression of the inducible genes were seen
at both the steady-state mRNA and tran-
scriptional levels, and the time courses for
these effects closely matched the time
course for chromium-induced DNA dam-
age and repair (10,12,14). Interestingly,
certain effects most closely correlated with
chromium-DNA monoadduct formation,
whereas other effects were more closely
associated with chromium-DNA cross-link
formation (10,12,14).
In contrast to chromium, the mecha-
nistic basis for the carcinogenic effects of
arsenic is still poorly understood. Arsenic
has generally been shown to be negative in
bacterial and mammalian mutagenesis
assays, and there is little evidence of DNA
damage induced by arsenic, although it has
been demonstrated to be a clastogen and
weak inducer of sister chromatid exchanges
in some systems (3,6). Arsenic causes
morphologic transformation, anchorage
independence, aneuploidy, and gene amp-
lification in mammalian cell culture assays
(6). These effects may be related to its
ability to alter DNA synthesis and DNA
repair, as well as fidelity of chromosome
segregation. Arsenite [As(III)] is approxi-
mately 4-fold more toxic than arsenate
[As(V)], although these two forms can be
inter-converted by redox pathways in vivo
(3). Arsenic(III) is readily methylated in
vivo, and the methylated forms have a low
interaction with macromolecules and are
readily excreted. However, the rate of
methylation differs among tissues and
species. The primary mechanism of
arsenic(V) toxicity is uncoupling of oxida-
tive phosphorylation, by substitution for
inorganic phosphate. Arsenic(III) also can
cause oxidative bursts in endothelial and
other cells, and is heat shock-mimetic,
inducing the classic heat shock and stress
responses of cells (15). Thus, its biologic
effects are more closely associated with
cytoplasmic rather than nuclear effects, and
DNA does not appear to be the primary
target for arsenic toxicity or carcinogenesis.
In this regard arsenic appears to act more
as a classic promoter such as the phorbol
ester 12-O-tetradecanoylphorbol-13-
acetate or hydrogen peroxide, although its
specific effects may be more complex.
Arsenic displays distinct interactions with
specific proteins in vivo, which may be the
basis for much of its specific toxic effects as
well as its carcinogenicity.
Most of the intracellular effects of
arsenic are attributed to arsenic(III) rather
than arsenic(V). Arsenic(III) binds avidly
to thiols in cells, both to small molecule
thiols such as glutathione as well as thiol-
containing proteins (3,16,17). Arsenic has
a particular avidity for hydrolases and can
compete with phosphate to inhibit
enzymes such as phosphoraldehyde and
glucose dehydrogenase (3). Many of the
cellular effects of arsenic can be ascribed to
its ability to elicit a heat-shock response
(15,16). Arsenic induces phosphorylation
of hsp27, increases expression of hsp27,
hsp70, and hsp90 through the heat-shock
factor, induces heme oxygenase, mdrl, and
quinone reductase gene expression, and
induces metallothionein expression by both
a transcriptional and posttranscriptional
mechanism, although arsenic is not a lig-
and for metallothionein protein binding
(3,18,19). Arsenic exhibits a strong prefer-
ential binding to the vicinal dithiol of the
glucocorticoid receptor, inhibiting binding
of glucocorticoid hormone but not altering
hsp9O binding (16,17). This effect is
extremely specific, as there is not a similar
effect on the closely related receptors for
androgen, estrogen, mineralocorticoids or
progesterone. Because at least one of the
model inducible genes we have used in our
studies, i.e., PEPCK is regulated by gluco-
corticoids, we predicted that this induction
pathway would also be markedly affected
by arsenic treatment. Other effects on
PEPCKexpression are also predicted to be
likely, as a result of arsenic effects on other
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specific response pathways and regulatory
proteins within the cell.
Thus, there is reason to believe that
both chromium and arsenic can have very
selective effects on activation of regulatory
pathways and expression of certain genes
in vivo, albeit through different mecha-
nisms. We are particularly interested in
testing the hypotheses that specific DNA
regulatory regions within the promoters of
targeted genes are responsible for mediat-
ing the cis effects, and that specific tran-
scriptional factors are responsible for
mediating the trans effects of these heavy
metals on inducible gene expression. Such
effects may be very important in under-
standing the overall effects of these and
other heavy metals on the carcinogenic
process. The purpose of these studies is to
explore these hypotheses in detail.
Materials and Methods
Animal and Cell Treatment
and Sample Preparation
All chemicals were purchased from Sigma
Chemical Co. (St. Louis, MO). Fertile
White Leghorn chicken eggs (Truslow
Farms, Inc., Chestertown, MD) were incu-
bated as previously described (20). Test
compounds were administered in solution
onto the inner shell membrane as pre-
viously described (21). Chromium(VI) was
administered as sodium dichromate
(Na2Cr207.2H20) at a dose of 50
pmol/kg in 100 pl H20. Arsenic(III) was
administered as sodium arsenite (NaAsO2)
at a dose of 100 pmol/kg in 100 pl H20.
Dexamethasone was administered as dexa-
methasone-21-phosphate in 10 1l H20 at
a dose of 5 jmol/kg embryo weight. For
steady-state mRNA studies, after embryo
treatment the livers were removed and
immediately frozen at -75°C. H4IIE rat
hepatoma and MDA-MB-435 (MDA) cells
were grown and treated essentially as previ-
ously described (22). UV-C (ultraviolet C)
doses (254 nm) were administered to cells
in 150-mm cell culture dishes with a UV
Stratalinker (Stratagene, Lajolla, CA) or
using a calibrated germicidal lamp at the
desired dose. Total cellular RNA was sub-
sequently isolated using a guanidine iso-
thiocyanate-cesium chloride gradient
technique exactly as previously described
(20). For the electrophoretic mobility shift
assays (EMSA), cells were washed with ice-
cold phosphate-buffered saline (pH 7.4),
containing 1.0 mM EDTA, protease
inhibitor mix (4 pg/ml leupeptin; 4
pg/ml soybean trypsin inhibitor; 1 mM
benzamidine), 7 pg/MI L-1-p-tosylamino-2-
phenylethyl chloromethyl ketone, and 0.1
mM dithiothreitol (DTT). Nuclear protein
soluble extract was isolated by a procedure
of Dignam et al. (23), as modified by
Barchowsky (24).
Measurement ofmRNA Levels and
EMSAAnalysis
Steady-state mRNA levels were measured
by a quantitative solution hybridization
assay using gene-specific 5'-[32P]-end-
labeled synthetic oligonucleotide probes,
exactly as previously described (20). This
assay has been shown to provide a sensitive,
linear, and quantitative measure of specific
steady-state mRNA levels (fmol of mRNA
per milligram of total RNA), and can accu-
rately determine differences in mRNA
expression of less than 20% (10,20,25,26).
The c-fos, c-jun, gadd45, gaddl53, and
PEPCKsolution hybridization probes we
used are synthetic cDNA oligonucleotides
corresponding to nucleotides 222-248
(27), 622-648 (28), 697-719 (29), 517-
540 (30), and 268-291 (31), respectively,
of the published sequences. Double-
stranded DNA consensus sequences for
AP-1 and nuclear factor-kappa B (NF-KB)
for use as EMSA probes were obtained
from Promega (Madison, WI). The Spl
double-stranded probe was synthesized
based on the Spl/EGRI site within the
mdrl gene promoter. Protein concentra-
tions were determined by a standard
absorbance assay (bicinchoninic acid
[BCA] assay; Pierce, Rockford, IL). The
EMSA analysis was performed essentially as
previously described (32) with the follow-
ing modifications (33): a high ionic load-
ing buffer was used containing 10 mM
Tris, 20 mM KCl, 0.2 mM DTT, 0.2 mM
EDTA, 4% glycerol, 0.2 pg/pl bovine
serum albumin, 0.02 pg/pl poly d(IC)
(GIBCO-BRL, Gaithersburg, MD), and
0.04 pg/pl salmon sperm DNA (pH 8.0).
A high ionic-strength running buffer was
also used containing 50 mM Tris, 380
mM glycine, 2.0 mM EDTA (pH 8.0).
Generation and Analysis ofPEPCK-
Luciferase Genetic Constructs
All DNA-modifying enzymes and lipofecta-
mine were purchased from GIBCO-BRL.
The pGL3 vectors and the luciferase assay
system were purchased from Promega. The
PEPCK-luciferase reporter vectors were
constructed by cloning a region of the
PEPCKpromoter into the multiple cloning
site of the pGL3 basic vector. Rat genomic
DNA from H4IIE cells was isolated and
used as a template for the PCR ampli-
flcation of the PEPCK promoter. The
sequences for the upper (forward) primers
were 5'-CTAGCTAGCCAATCACCCCT
(NheI, -592 of the rat PEPCKpromoter
region) and 5'-CTAGCTAGCCATGT
CCCTGCCCCC (NheI, -1162 of the rat
PEPCKpromoter region); and the sequence
of the lower (reverse) primer was 5'-
GGAAGATCTCTACCTTTCTT (Bgl II,
+87 of the rat PEPCKpromoter region). All
plasmids used were grown in Escherichia coli
JM109 strain. The PEPCKpromoter frag-
ments were digested with NheI and BgIII
enzymes and ligated into pGL3. Plasmids
containing inserts were sequenced with an
ABI PRISM DyeDeoxy Terminator Cycle
Sequencing kit (Applied Biosystems, Foster
City, CA). All sequences were checked
against GenBank PEPCKsequences using
the Blast sequence analysis program to
ensure sequence specificity. Plasmid DNA
was purified using Qiagen columns
(Qiagen, Valencia, CA) and transfected into
H4IIE rat hepatoma cells using the lipo-
fectamine technique (GIBCO-BRL). To
obtain stable transfectants, cells were
cotransfected with two types of plasmids:
pGL3 reporter vectors with different pro-
moters plus pSV2neo that confers resistance
to neomycin. Cells were selected in G418
and resistant colonies were subcloned and
checked for PEPCK-luciferase insertion.
For the luciferase assay, cells were lysed in
the luciferase reporter buffer in the wells
according manufacturer's instructions
(Luciferase assay system, Promega). Luci-
ferase activity was measured using a 96-well
plate luminometer (Dynatech Laboratories,
Chantilly, VA). Protein concentrations were
determined by a standard absorbance DC
(detergent compatible) protein assay
(Bio-Rad, Hercules, CA).
Statistica Analysis
Data were analyzed for statistical significance
by ANOVA, Student's t-test, and non-
parametric analysis, where appropriate, using
the Instat and Prism software programs
(GraphPad Software, San Diego, CA).
Results
Initial experiments were conducted to
examine whether there were preferential
effects of chromium and arsenic on expres-
sion of a model-inducible gene, PEPCK, in
14-day chick embryo livers. The chick
embryo represents a simple, inexpensive,
and easily manipulated in vivo model and
has been an excellent system for examining
effects of carcinogens on gene expression
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based on our previous studies (10-13,
34-36). Chick embryo development has
been extensively characterized, providing a
large background of information about its
embryology, physiology, and biochemistry.
This model has been used to investigate the
genotoxicity of over 50 chemicals using a
wide variety of genetic end points, includ-
ing chromosomal damage, sister chromatid
exchange, inhibition of DNA synthesis,
unscheduled DNA synthesis, carcinogen-
DNA binding, and DNA alkaline elution
(10,14,21,37-39). The chick embryo also
possesses an active, highly inducible
hepatic mixed-function oxidase enzyme
system capable of metabolizing indirect-
acting mutagen-carcinogens to active
forms (20,21,26,37,38,40). The chick
embryo can also be used to specifically
examine the developmental effects of
agents on an embryonic system and mimics
the human fetus in many important
aspects with regard to its toxicology
(21,37,38,40,41). Thus, this system repre-
sents an excellent nonmammalian whole
animal toxicology model.
The highest doses of chromium(VI)
and arsenic(III) that caused no overt toxic-
ity or lethality in dose-response experi-
ments were determined to be 50 imol/kg
and 100 pmol/kg, respectively (10,12,42).
At these doses there is little or no effect on
overall DNA, RNA, or protein synthesis,
and the embryos can be hatched normally
with no obvious toxic effects (10,12,42).
Using these doses, 14-day embryos were
A
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treated with a single administration of
chromium or arsenic, and mRNA expres-
sion of various inducible and constitutive
genes was measured over time (Figure
lA-C). Chromium (Figure IA) or arsenic
(Figure iB) treatment significantly
increased the basal expression of PEPCK,
but had no effect on expression of ,-actin
(Figure 1C). Chromium and arsenic also
significantly altered the response of the
PEPCKgene to glucocorticoid induction
(Figure 1A,B). Chromium increased the
induction response of PEPCKto glucocor-
ticoids initially (1-2 hr) but at later times
almost completely suppressed the response
of PEPCKto its normal induction signal
(Figure IA). Arsenic had similar effects,
although the magnitude of the response was
greater and occurred over a more protracted
time than the response to chromium
(Figure 1B).
These effects were then examined in the
H4IIE rat hepatoma cell line to investigate
the molecular basis for this phenomenon.
This cell line expresses PEPCKin a basal
and hormone-inducible manner similar to
that of the liver in vivo, and has been used
extensively to examine PEPCKregulation
[reviewed by Granner et al. (43) and Lucas
and Granner (44)]. Initial experiments
established the toxicity dose-response to
chromium and arsenic using a colony-
forming assay as a measure of cell survival
(Figure 2). These experiments established
the maximal noncytotoxic doses as well
as the minimal doses which produced
B
0
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complete cell death. These were used in
subsequent experiments to examine res-
ponses to low (i.e., noncytotoxic) versus
high (i.e., cytotoxic) doses of heavy metals.
Using these low doses, the effects of
chromium and arsenic on PEPCK expres-
sion were examined in the H4IIE cells, and
compared to the effects of mitomycin C
(MMC), an organic DNA cross-linking
agent with similar genotoxic properties as
chromium(VI). Figure 3 shows that
150
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Figure 2. Cytotoxicity of chromium(VI) and arsenic(ll)
in rat hepatoma H411E and human breast carcinoma
MDA-MB-435 cell lines. Cells were treated with
chromium or arsenic for 4 hr and cytotoxicity was
assessed by a colony-forming assay as described in
"Materials and Methods." Data are expressed as a
percent of control colonies formed. Each data point
represents the mean±SD of values from three sepa-
rate plates. *, MDA cells treated with arsenic; *,
MDA cells treated with chromium; A, H411E cells
treated with arsenic; *, H411E cells treated with
chromium.
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Figure 1. Effects of chromium(V1) and arsenic(lll) on basal and inducible PEPCKmRNA expression and on constitutive p-actin mRNA expression in 14-day chick embryo liver in
vivo. Embryos were treated for various times with a single dose of either 50 pmol/kg chromium(VI) as sodium dichromate or 100 pmol/kg arsenic(lil) as sodium arsenite, and
expression of PEPCKand ,B-actin mRNA was measured in total liver RNA samples by solution hybridization using a gene-specific oligonucleotide probe as described in
"Materials and Methods." Alternatively, embryos were treated with chromium or arsenic and beginning at various times afterward were treated with 5 pmol/kg dexametha-
sone for exactly 3.5 hr to measure effects on hormone-inducible PEPCKexpression. Data are expressed as a percent of the basal control value (0 hr, 100%) and are graphed as
time of total chromium or arsenic treatment (basal, constitutive) or time of chromium or arsenic treatment before the beginning of dexamethasone induction (induced).
Asterisks denote values that were significantly different from the appropriate control (basal or induced) at p< 0.01. (A) Effects of chromium(VI) on basal (0) and inducible (a)
PEPCKexpression. Each data point represents the mean ± SEM of values from four to eight individual animals [data reprinted from J. McCaffrey et al. (12) with permission].
(B) Effects of arsenic(lil) on basal (0) and inducible (a) PEPCKexpression. Each data point represents the mean ± SEM of values from four to six individual animals. (C) Effects
of chromium(VI) (0) and arsenic(lil) (a) on P-actin expression. Each data point represents the mean±SEM of values from four to six individual animals lchromium data
reprinted from Hamilton and Wetterhahn (10) with permission].
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chromium and arsenic significantly sup-
pressed basal expression of PEPCK in a
manner similar to MMC. We had previ-
ously shown that chromium, arsenic, and
MMC also suppressed expression in these
cells of the inducible gene mdrl, which
codes for P-glycoprotein, but has no effect
on several constitutive genes (22,42). Thus,
this appeared to be a good model for exam-
ining in detail the mechanism by which
these metals selectively affect inducible gene
expression in cells.
We then examined the effects of
chromium and arsenic on the nudear levels
of various transcription factors that might be
associated with such changes in gene expres-
sion. It has been postulated that toxins can
alter gene expression by activation of cell-sig-
naling pathways leading to increases in
nuclear transcription factor levels and/or
activities leading to altered mRNA expres-
sion. Cells were treated with low and high
doses of metals and nudear extracts were iso-
lated. Transcription factor binding was
determined using EMSA analysis. An exam-
ple of data generated in these studies is
shown in Figure 4, which demonstrates a
significant effect of a 1-hr noncytotoxic
chromium treatment on nuclear binding lev-
els of the transcription factor Spl . Using this
approach, we then examined in detail the
effects of chromium and arsenic on nuclear
levels of AP-1, NF-KB, and Spl transcrip-
tion factors, since these factors have been
implicated in the regulation of both PEPCK
and mdrl genes, which are affected by these
agents (3,43,45-49). As summarized in
Table 1, there were specific effects of each
agent on transcription factor binding that
were agent-, dose-, factor- and cell line-
dependent. Both chromium and arsenic gen-
erally caused significant increases in AP-1
binding in both cell lines at both doses, with
the exception that the high dose of
chromium suppressed AP-1 binding in the
MDA cells. In contrast, the effects on Spl
binding were quite variable. Chromium sig-
nificantly increased Spl binding in the
MDA cells, whereas it had no effect on SpI
binding levels in the H4IIE cells. Con-
versely, arsenic had no effect on Spl binding
in the MDA cells, whereas it decreased Spl
in the H4IIE cells at the high dose. Metal
effects on NF-KB binding were very cell-type
specific. Arsenic had little or no effect on
NF-icB binding in the MDA cells, whereas
chromium increased binding, and neither
agent had any effect on NF-KB in the H4IIE
cells. Taken together, these results suggest
that effects of chromium and arsenic on
nudear levels of specific transcription factors
may be a component of tissue-specific alter-
ations in gene expression caused by these
metals. These effects may contribute to the
overall biologic effects of these metals in
humans and may play a role in long-term
effects oflow-dose exposures such as occur in
metal-induced carcinogenesis.
Previously, it had been demonstrated
that high-dose UV or y irradiation as well as
treatment with certain chemical carcinogens
can stimulate a characteristic response pat-
tern in cells that has been called the UV
response (50-52). Since activation of cer-
tain transcription factors, particularly AP-1
and NF-iKB, has been shown to be a
component of the UV response pathway
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Figure 4. Effects of chromium(VI) on levels of nuclear
binding to the Spl transcription factor recognition
sequence in rat hepatoma H411E cells in culture. Cells
were treated with 2 pM chromium(VI) for the indicated
times, and total nuclear protein extracts were isolated
as described in "Materials and Methods."
Electrophoretic mobility shift analysis was performed
using a radiolabeled duplex oligonucleotide fragment
corresponding to the Spl recognition sequence from
the human MDR1 promoter region and levels of Spl
binding (arrow) were analyzed as described in
"Materials and Methods." Blank, no nuclear extract
added; 0 hr control, extract from cells treated with
solvent alone.
* *
0 1 2 3 4 5 6
Time after treatment, hr
Figure 3. Effects of chromium(V1), arsenic(lil), and mit-
omycin C on basal PEPCKmRNA expression in rat
hepatoma H411E cells in culture. Cells were treated
with 2 pM chromium(VI) (0); 0.33 pM arsenic(lil) (m);
or 0.1 pM MMC (A) for 4 hr in incomplete medium and
PEPCK mRNA expression was measured as described
in "Materials and Methods" and in Figure 1. Each data
point represents the mean ± SD of values from three to
four separate flasks. Asterisks denote values that were
significantly different from the appropriate control
(basal or induced) at p< 0.01.
Table 1. Summary of effects of chromium(VI) and arsenic(lil) on nuclear transcription factor binding levels in H411E
rat hepatoma and MDA-MB-435 human breast carcinoma cell lines.
AP-1 Spl NF-KB
Cells and treatmenta Changeb Time Change Time Change Time
MDA cells
Cr low 10-fold 1 hr 17-fold 1 hr 10-fold 1 hr
Cr high 0.3-fold 2 hr 25-fold 1 hr 4-fold 1 hr
As low 3-fold 1 hr No effect 3-fold 2 hr
As high 8-fold 1 hr No effect 2-fold 1 hr
H411E cells
Cr low 12-fold 4 hr No effect No effect
Cr high 12-fold 4 hr No effect No effect
As low 9-fold 2 hr No effect No effect
As high 7-fold 0.5 hr 0.5-fold 4 hr No effect
aCells were treated with chromium(VI) as sodium dichromate at low (2 pM) or high (20, 100 pM) doses, or with
arsenic(lll) as sodium arsenite at low (0.33-1 pM) or high (100, 333 pM) doses for up to 4 hr followed by EMSA
analysis of nuclear protein binding as described in "Materials and Methods" and in Figure 4, using probes for AP-
1, Spl, and NF-kB binding. hSignificant changes in binding are expressed as the fold increase or decrease in
nuclear binding levels relative to the solvent-treated controls at the maximal time point indicated after the begin-
ning of heavy metal treatment.
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(50,51,53,54), we investigated in more
detail whether this could be contributing to
effects of metals on gene expression in our
experiments. Table 2 summarizes the results
of studies examining the effects of
chromium and arsenic on hallmarks of the
UV response pathway, i.e., mRNA expres-
sion of c-fos and c-jun (components of the
AP-1 transcription factor), and gadd45 and
gadedl53 (growth arrest- and DNA damage-
inducible genes), and increases in nuclear
levels of AP-1 and NF-iKB. This was com-
pared to effects ofUV, tumor necrosis factor
a (TNF-a), and y-irradiation on these para-
meters and on expression of PEPCKand
mdrl mRNA. Although UV, tumor necro-
sis factor [3 (TNF[3), and y-irradiation
induced most or all of the hallmarks of the
UV response in these cells, chromium,
arsenic, and MMC did not alter the major-
ity of these parameters. The exception was
an increase in nuclear AP-1 levels by both
metals, but this response was not accompa-
nied by the predicted increases in c-fos or c-
jun mRNA expression. In contrast,
chromium, arsenic, and MMC all altered
mRNA expression of PEPCK and mdrl,
whereas UV, TNFa, andy-irradiation did
not. These results demonstrate conclusively
that the effects of noncytotoxic doses of
chromium and arsenic (and MMC) on gene
expression do not involve activation of the
UV response pathway per se.
We then examined whether specific
genetic elements within the promoters of
target inducible genes could be responsible
for mediating the effects of chromium and
arsenic on their expression. Constructs con-
sisting of portions of the rat PEPCKgene
promoter were fused with the luciferase
reporter gene and transfected into H4IIE
cells to generate stably transfected cell lines
with integrated copies of the transgene in
their genome. The PEPCK-luciferase gene
was basally expressed and fully hormone
responsive in these cell lines in a manner
similar to that of the native PEPCKgene
(Figure 5A,B). In addition, the constructs
containing either 1.2 or 0.6 kb of normal
rat PEPCKpromoter were fully responsive
to chromium, arsenic, and MMC, suggest-
ing that this region of the PEPCK pro-
moter is sufficient to confer carcinogen
sensitivity to another gene and therefore
contains a target(s) for their effects. It fur-
ther suggests that integration into nuclear
chromatin structure is important for elicit-
ing these effects. Interestingly, the two
wild-type constructs differed qualitatively
from each other in their basal response.
The 1.2-kb construct exhibited a sig-
nificant decrease, whereas the 0.6-kb con-
struct exhibited a significant increase in
PEPCK-luciferase expression in response
to each of the three agents (Figure 5A).
This suggests that an element(s) between
-0.6 and -1.2 kb of the PEPCK promoter
can contribute qualitatively to the basal
response of this promoter to these agents.
It had previously been shown that the
proximal 0.6 kb of the rat PEPCK pro-
moter was sufficient to confer normal hor-
mone responsiveness to heterologous
constructs (43). Both the 1.2- and 0.6-kb
construct cell lines exhibited a normal dex-
amethasone response (Figure 5B), and
both constructs also exhibited a complete
inhibition of their dexamethasone response
following treatment with each of the three
agents (Figure 5B).
Constructs were then transfected with a
1.2-kb portion of the PEPCKpromoter in
which either the two tandem glucocor-
ticoid response elements or the two adja-
cent accessory factor elements had been
mutated using a site-directed mutagenesis
technique that leaves the surrounding
sequences intact. Mutation of these ele-
ments by deletion had previously been
shown to significantly decrease or abolish
Table 2. Comparison of effects of chromium(VI), arsenic(lil), and mitomycin C on inducible gene expression and on
aspects of the UV response pathway in rat hepatoma H411E cells in culture.
UV TNFa y-irradiation MMC Cr(VI) As(lll)
UV responsea
c-fos lc-jun mRNA + + + 0 ND ND
gadd45Igaddl53 mRNA + 0 + 0 0 0
Nuclear AP-1 binding + + + 0 + +
Nuclear NF-iB binding + + + 0 0 0
Inducible genes
PEPCKmRNA 0 0 0 - - -
mdrl mRNA 0 0 0
ND, not determined. "Cells were treated and analyzed as described in "Materials and Methods" and in Figure 4
and Table 1. UV, 20 J/m2 UV-C 1-4 hr; TNFa, 20 U/mI 1-4 hr; y-irradiation, 300 rad y-irradiation 1-4 hr; MMC, 0.1
pM MMC 1-6 hr; Cr(VI), 2 pM chromium(VI) 1-6 hr; 0.33 pM arsenic(lIl) 1-6 hr; +, 2-fold or greater increase; -, 2-
fold or greater decrease; 0, no significant change from control (see "Materials and Methods" and text).
hormone-inducible response of this
promoter (43,44). As expected, although
these constructs displayed a normal basal
expression (Figure 5A), they had a signifi-
cantly reduced responsiveness to induction
by dexamethasone (Figure 5B). These con-
structs did not show any effect of treat-
ment with chromium, arsenic, or MMC
followed by dexamethasone (Figure 5B).
Interestingly, their basal expression was
also observed to be completely refractory to
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Figure 5. Effects of chromium(VI), arsenic(lil), and mit-
omycin C on basal and hormone-inducible expression
of a PEPCK-luciferase genetic construct transiently
and stably transfected into rat hepatoma H411E cells in
culture. Abbreviations: 1.2, 1.2-kb wild-type promoter;
0.6, 0.6 response elements; GRU (glucocorticoid
response unit) 1.2 kb promoter with site-directed
mutations in thge two glucocorticoid response ele-
ments; AF (accesory factor region), 1.2-kb promoter
with site-directed mutations in the two accessory fac-
tor elements (see text). Constructs containing 0.6 or
1.2-kb of the rat PEPCK promoter region fused to the
luciferase reporter gene were generated and cells
were transfected as described in "Materials and
Methods." Cells were treated with 2 pM chromium(VI),
0.33 pM arsenic(lil), or 0.1 pM MMC as indicated in
the legend for 4 hr in incomplete medium and basal
PEPCK-luciferase expression was measured 20 hr
later by a luminometer assay for luciferase activity as
described in "Materials and Methods" (A).
Alternatively, cells were treated with chromium,
arsenic, or MMC, and beginning 4 hr later, cells were
treated with 0.1 pM dexamethasone for 20 hr to mea-
sure effects on hormone-inducible PEPCK-luciferase
expression (B). Data are expressed as a percent of the
basal control values. Each bar represents the mean ±
SD of values from three individual wells.
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chromium, arsenic, or MMC treatments
(Figure 5A). These results suggest that the
responsiveness of the PEPCKgene to
glucocorticoid induction is an important
component of its ability to respond to
chromium and arsenic treatments at both
the basal and hormone-inducible level.
Discussion
The principal purpose of these studies was to
develop systems to enable us to determine at
the molecular level the basis for the preferen-
tial effects of the carcinogenic heavy metals
chromium(VI) and arsenic(III) on inducible
gene expression. We had previously exam-
ined the preferential effects of 16 different
chemical carcinogens, induding the geno-
toxic metals chromium(VI) and cisplatin,
and other organic genotoxic agents that
induce different types of DNA damage, on
the expression of several different model
inducible genes. Those studies demon-
strated that treatment of 14-day chick
embryos with a single administration of
chromium(VI), at a dose that produced no
overt toxicity but which caused significant
levels of DNA damage (14), had profound
effects on expression of several inducible
genes but had no effect on expression of
several constitutively expressed genes (10).
Both the basal and inducible expression of
the inducible ALA synthase, CYP2H1 and
PEPCKgenes were markedly affected by
the chromium treatment, whereas the albu-
min, transferrin, and 3-actin genes were
refractory to this treatment. The effects on
expression of the inducible genes were
seen at both the steady-state mRNA and
transcriptional levels, and the time courses
for these effects closely matched the time
course for chromium-induced DNA dam-
age and repair (10,12,14). Interestingly,
certain effects most closely correlated with
chromium-DNA monoadduct formation,
whereas other effects were more closely
associated with chromium-DNA cross-
link formation (10,12,14). This same gen-
eral phenomenon, i.e., preferential effects
on inducible genes and correlation with
DNA damage and repair, has also been
observed in this system with a large num-
ber of other genotoxic and carcinogenic
agents. These include the cross-linking
agents cisplatin (11), and MMC (35); the
direct-acting, simple alkylating agents
methyl methanesulfonate (MMS), methyl-
nitrosourea, ethyl methanesulfonate, and
ethylnitrosourea (34); several agents that
induce bulky monoadduct lesions in DNA,
including benzo[a]pyrene, aflatoxin B1,
7, 12-dimethylbenz[a]anthracene, and
2-acetylaminofluorene (13); a chemical
that induces strand breaks, bleomycin
(11); and several synthetic acridine-based
mono- and bis-intercalating agents (42).
The results of many of these studies have
recently been summarized (11).
The preferential effects of each of these
agents strongly correlated with DNA dam-
age, which supports the general hypothesis
that alterations in gene expression can be
used as a marker for DNA damage in vivo.
Although the inducible genes were all
responsive to DNA-damaging agents, the
time course, direction, and magnitude of
each response was both agent specific and
gene specific. However, similarities in spe-
cific effects among groups of agents were
based on the type ofDNA damage induced,
rather than the chemical structure, metabo-
lism, lipophilicity, etc., of the agents them-
selves, which lends further support to the
hypothesis that induction of DNA damage
was the basis for the preferential effects on
inducible gene expression. Others have also
examined effects on gene expression by
some of these agents as well as other car-
cinogens (55-58) that cause a variety of
DNA lesions, including simple alkylations,
bulky lesions, and cross-links. All of the car-
cinogens tested to date have been demon-
strated to selectively alter inducible gene
expression. We and others (55-57) have
examined a number of different inducible
genes; all responded to carcinogen treat-
ment. In contrast, none of the constitutively
expressed genes tested (p-actin, transferrin,
albumin, and ax-tubulin) were responsive.
Effects on inducible gene expression have
been observed in both the rat and chick
embryo in vivo (10,13,34,55,59) and in pri-
mary chick embryo, adult rat, and rat
embryo hepatocytes and rat hepatoma cell
lines in culture (56-58). All of these sys-
tems show similar responses. Thus, carcino-
gen-induced alterations in inducible gene
expression are a general phenomenon, and
responsiveness appears to be independent of
the specific system, carcinogen, gene, or
induction pathway studied.
In contrast to these organic and
inorganic carcinogens that are believed to
principally target DNA as their mechanism
of action, the mechanism of action of
nongenotoxic carcinogens such as the
heavy metals arsenic and cadmium is not
well understood. However, it is known
that these agents interact with specific sub-
sets of proteins, principally through
sulfhydryl interactions, and it has been
postulated that they may act through epi-
genetic mechanisms to act as carcinogens.
We had hypothesized that arsenic may also
specifically and preferentially alter inducible
gene expression much like chromium, but
through a different mechanism than that of
chromium or the other genotoxic agents.
The goal of these studies was to examine
this hypothesis in detail. Our results indi-
cate that chromium and arsenic both pref-
erentially alter inducible gene expression,
and in a similar manner. Each agent had
significant effects on basal and hormone-
inducible expression of a model inducible
gene, PEPCK, in both the chick embryo in
vivo system and in rat hepatoma H4IIE
cells in culture. Each agent also altered
expression of PEPCK-luciferase genetic
constructs in which their effects on basal
and inducible expression were strongly cor-
related with the responsiveness of the trans-
gene to glucocorticoids, suggesting that this
pathway is important for the response and
may be the primary target. These results
indicate that this genetic approach will be
useful for identifying specific regulatory
pathways that mediate these responses.
It is interesting to note that the effects
of chromium and arsenic on the integrated
constructs containing 1.2 kb of promoter
region were very similar to those on the
native rat PEPCKgene in the H4IIE cells,
i.e., a suppression in both basal and hor-
mone-inducible expression, suggesting
that this region of the promoter is suffi-
cient to replicate the metal effects on the
normal gene. The effects of chromium and
arsenic on the 0.6 kb construct, in con-
trast, were more similar to those seen for
PEPCKin the chick embryo liver, i.e., an
increase in basal expression and a decrease
in hormone responsiveness, suggesting
that the distal 0.6 kb provided additional
elements that qualitatively change the
response of the rat PEPCKgene to these
agents. A complete loss of basal respon-
siveness of the rat PEPCKgene promoter
to chromium and arsenic was observed in
mutated constructs in which there was also
a loss of hormone responsiveness. This is
very similar to what had previously been
observed in the chick embryo system, in
which the responsiveness of the native
chicken PEPCKgene was intimately asso-
ciated with its response to dexamethasone
(12). In that study, we showed that the
PEPCKgene lost its chromium sensitivity
concomitant with the normal develop-
mental loss of liver PEPCKhormone
responsiveness that occurs between 14 and
17 days of embryonic development
(12,60), even though the liver PEPCK
gene was still basally expressed and still
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responsive to induction by cAMP at 17
days (12). In addition, we have recently
observed over that same developmental
time period that the kidney PEPCKgene
gained hormone responsiveness, and con-
comitantly gained sensitivity to chromium
treatment (42). However, in a similar
developmental study, we observed that the
chick embryo liver PEPCK gene was
refractory to the effects ofMMC at 8 days
of development even though it was fully
glucocorticoid inducible (61). Thus, hor-
mone responsiveness appears to be neces-
sary but insufficient by itself to elicit a
carcinogen response in this gene. In that
study, the PEPCKgene became MMC
sensitive by day 10 of embryonic develop-
ment, concomitant with a major change in
the chromatin structure of the PEPCK
gene promoter region (61). These results
suggest that both glucocorticoid respon-
siveness and chromatin structure are criti-
cal for the selective responsiveness of the
PEPCKgene to carcinogen treatment.
Chromium and arsenic also altered
nuclear transcription factor binding,
although the patterns were different for the
two agents and were also dose- and cell-type
specific. Previous studies by Fornace and co-
workers (52,53,62) and others (50,51,54)
reported that treatment of cells with high
doses of UV irradiation or other cytotoxic
agents causes a characteristic UV response in
cells. The response to UV irradiation itself
was best characterized and involved a rapid
increase in expression of mRNAs for c-fos
and c-jun (components of AP-1), growth
arrest and DNA damage-inducible (gada)
genes, especially gadd45 and gaddl53, as
well as other genes (53,54,63). There was
also a rapid increase in binding ofAP-1 and
NF-KB to their target DNA regulatory
sequences (50,51). Other agents that were
reported to mimic aspects of this response
included X-irradiation, oxidative stress (e.g.,
by hydrogen peroxide), and certain DNA-
damaging agents, including MMS, cisplatin,
and MMC, although only at high, i.e.,
overtly cytotoxic, doses. We investigated
whether our treatments stimulated aspects
of the UV response as a number of
inducible genes have been shown to be regu-
lated by AP-1 and/or NF-icB, including
PEPCK(64) and mdrl (65) that have been
shown to be sensitive to chromium and
arsenic in our studies. However, our results
clearly indicate that noncytotoxic doses of
chromium and arsenic are not acting
through the mammalian UV response path-
way to exert their preferential effects on
inducible gene expression.
We observed a significant increase in
both AP-1 and Spl binding by low-dose
chromium treatments, whereas arsenic
increased AP-1 but had little or no effect on
Spl at low doses. Chromium significantly
increased NF-icB binding and arsenic
induced modest increases in NF-iKB at low
doses in the MDA cells, although neither
agent had a significant effect on NF-icB
binding at low or high doses in the H4IIE
cell line. However, chromium and arsenic
had no effect on other hallmarks of the UV
response pathway. In addition, positive
controls such as UV or TNFa that stimu-
late the UV response did not alter PEPCK
expression. Thus, effects of chromium and
arsenic on the UV response may involve
apoptotic or other mechanisms that occur
only at very high doses and represent late
events, but which are separate from the
pathways leading to alterations in gene
expression that occur at lower doses. The
best chemical DNA-damaging agent to
induce the UV response to date is the sim-
ple direct-acting alkylating agent MMS
(66,67). However, in addition to DNA
damage, MMS also induces large amounts
of protein adducts including protein cross-
links (68), suggesting a possible alternative
mechanism for stimulation of the UV
pathway (69,70). It is possible that chemi-
cal stimulation of the UV pathway requires
a certain threshold of nonspecific protein
adducts that can only be obtained at very
high doses of these agents but that are not
critical to the carcinogenicity of these
agents at lower doses. Similarly, arsenic has
been shown to be heat-shock mimetic,
although this also occurs at much higher
doses than those which led to alterations in
PEPCKgene expression in this study.
However, lower doses did not significantly
alter heat-shock protein expression in pre-
liminary studies (42). Thus, it is also
unlikely that this pathway is the principal
mediator of these effects at the lower doses.
Figure 6 summarizes our current model
for the actions of chromium and arsenic on
PEPCKgene expression. Inducible gene
expression ultimately involves the conver-
gence of cell signaling pathways with
DNA-chromatin at the level of the gene
promoter. Thus, it is possible that two dif-
ferent agents such as chromium and arsenic,
which may act at different points of the
same pathway, might lead to similar effects
on expression of a targeted inducible gene.
Chromium is proposed to act principally
through its action as a DNA-damaging
agent. We hypothesize that chromium-
induced DNA lesions lead to alterations in
Cr(VI) As(lIl)
CrMVI)
MetaboIism~\
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Figure 6. Model for preferential effects of chromium(VI)
and arsenic(lil) on inducible gene expression. TFs, tran-
scription factors. Chromium(VI) enters the cell as
CrO4-2 through nonspecific anion transport pathways
and is metabolized through a variety of small molecule
and enzyme-reductive pathways to Cr(V), Cr(IV), and
Cr(lIl) species that can interact directly with DNA-chro-
matin to form monoadducts, DNA interstrand,
intrastrand and DNA-protein cross-links, and other
forms of DNA damage. These intermediates may also
activate or repress specific transcription factors either
directly or indirectly through signaling pathways.
Arsenic(lil) can also enter the cell and activate tran-
scription factors directly or indirectly. Arsenic does not
directly interact with DNA but may also indirectly alter
chromatin structure through interaction with chromoso-
mal proteins. These chromium and arsenic effects on
transcription factors and DNA-chromatin ultimately
converge at the promoters of targeted inducible genes
such as PEPCK, causing alterations in specific
DNA-protein interactions that ultimately lead to
changes in transcription and gene product expression.
specific DNA-protein interactions within
the chromatin of an inducible gene pro-
moter, leading to changes in transcription
of that gene. Inducible genes such as
PEPCKmay be preferentially susceptible to
these effects because of their large DNase-
hypersensitive regions which represent areas
of nonnucleosomal decondensed chromatin
and regions of complex DNA-transcription
factor interactions. In addition, chromium
also has significant effects on nuclear levels
of specific transcription factors, and these
are likely to contribute to the overall effects
of chromium on inducible gene expression.
We further propose that arsenic acts princi-
pally through direct or indirect effects on
specific transcription factors and other sig-
naling pathways rather than on DNA per
se. Arsenic may also be able to affect chro-
matin structure within an inducible gene
promoter through mechanisms involving
alterations in histone and/or nonhistone
chromosomal proteins. Collectively, these
effects may ultimately lead to alterations in
specific DNA-protein interactions within
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inducible gene promoters in a manner
similar to that of chromium. We have
demonstrated that chromium and arsenic
have similar effects on expression of the
hormone-regulated PEPCKgene, both in
the chick embryo in vivo and in the H4IIE
cell line in culture. These effects are closely
correlated with glucocorticoid regulation of
this gene through the glucocorticoid recep-
tor pathway and its DNA recognition ele-
ments within the PEPCKpromoter region.
Examining the details of how chromium
and arsenic specifically alter this regulatory
pathway will be the focus of future studies.
In summary, we have examined the
mechanistic basis for the strong preferential
effects of the heavy metals and human car-
cinogens chromium(VI) and arsenic(III)
on inducible gene expression. Our studies
indicate that each of these agents has spe-
cific effects on transcription factor binding
and expression of certain genetic constructs
that may provide insight into the cell sig-
naling and gene regulatory pathways that
mediate their carcinogenic effects in vivo. A
combination of both cis effects involving
specific regions of the PEPCK promoter
and their chromatin structure, and trans
effects involving effects on specific tran-
scription factors appear to work in concert
to contribute to the overall effects of these
heavy metals on inducible gene expression.
Determining the mechanisms by which
these carcinogenic metals may selectively
alter gene expression would have important
implications for understanding the molec-
ular basis for the impact of these agents on
the carcinogenic process and overall human
cancer incidence in exposed populations.
Although each of these agents may have
specific effects and act through indepen-
dent mechanisms, they may also have pro-
found but different effects when present in
different combinations in the environment.
Understanding these interactions at the
molecular level is critical for an accurate
assessment of the overall health effects of
these substances on the human population.
Elucidating these molecular events may
also eventually provide sensitive biomark-
ers for evaluating human exposures, for
example, by defining a specific transcrip-
tion factor, signaling pathway, or sentinel
gene that might be indicative of prior
arsenic or chromium exposure, much as
metallothionein expression can serve as an
indicator of cadmium exposure. This will
first require a more detailed understanding
of the basis for these effects.
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